AIM ImmunoTech Inc is trading 11.4% down at $0.73 as the sharp pullback from last week’s trial-fueled spike continues.
- The stock more than doubled recently following positive pancreatic cancer trial progress and enrollment news.
- Recent sessions show steady selling and profit-taking as speculative momentum cools and traders lock in gains.